Modulated release of OP-1 and enhanced preosteoblast differentiation using a core-shell nanoparticulate system

Journal of Biomedical Materials Research - Part A

Volumn 91, Issue 3, 2009, Pages 919-928

  Haidar, Ziyad S ^a   Azari, Fereshteh ^a   Hamdy, Reggie C ^a,b   Tabrizian, Maryam ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Alginate; Alkaline phosphatase; Bone morphogenetic protein(s); Cell viability; Chitosan; Controlled drug release; Core shell nanoparticles; Liposomes; Self assembly

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN(S); CELL VIABILITY; CONTROLLED DRUG RELEASE; CORE-SHELL NANOPARTICLES;

ALGINATE; BONE; CELL MEMBRANES; CHITIN; CHITOSAN; HYDROGELS; LIPOSOMES; NANOPARTICLES; PHOSPHOLIPIDS; PROTEINS; SELF ASSEMBLY; SHELLS (STRUCTURES); SODIUM; SUGAR (SUCROSE);

GENE TRANSFER;

ALGINIC ACID; ALKALINE PHOSPHATASE; CHITOSAN; LIPOSOME; NANOPARTICLE; OSTEOGENIC PROTEIN 1;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; COLORIMETRY; CYTOTOXICITY; MOUSE; NONHUMAN; OSTEOBLAST;

3T3 CELLS; ALKALINE PHOSPHATASE; ANIMALS; BONE MORPHOGENETIC PROTEIN 7; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; KINETICS; MICE; NANOPARTICLES; NANOTECHNOLOGY; OSTEOBLASTS; PARTICLE SIZE; PROTEINS;

EID: 70350324646     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32292     Document Type: Article

References (56)

1. Ripamonti U, Ramoshebi LN, Matsaba T, Tasker J, Crooks J, Teare J. Bone induction by BMPs/OPs and related family members in primates: The critical role of delivery systems. J Bone Joint Surg Am 2001;83:116-127. (Pubitemid 32298356)
2. Sykaras N, Opperman LA. Bone morphogenetic proteins (BMPs): How do they function and what can they offer the clinician? J Oral Sci 2003;45:57-73.
3. Xiao YT, Xiang LX, Shao JZ. Bone morphogenetic protein. Biochem Biophys Res Commun 2007;362:550-553.
4. Termaat MF, Den Boer FC, Bakker FC, Patka P, Haarman HJThM. Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am 2005;87:1367-1378. (Pubitemid 40756643)
5. Saito N, Okada T, Horiuchi H, Ota H, Takahashi J, Murakami N, Nawata M, Kojima S, Nozaki K, Takaoka K. Local bone formation by injection of recombinant human bone morphogenetic protein-2 contained in polymer carriers. Bone 2003;32:381-386. (Pubitemid 36407538)
6. Giannobile WV, Ryan S, Shih MS, Su DL, Kaplan PL, Chan TC. Recombinant human osteogenic protein-1 (OP-1) stimulates periodontal wound healing in class III furcation defects. J Periodontol 1998;69:129-137. (Pubitemid 28130763)
7. Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, White KH, Coughlin JE, Tucker MM, Pang RH. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992;267:20352-20362.
8. Vukicevic S, Stavljenic A, Pecina M. Discovery and clinical applications of bone morphogenetic proteins. Eur J Clin Chem Clin Biochem 1995;33:661-671.
9. Cook SD, Rueger DC. Osteogenic protein-1: Biology and applications. Clin Orthop Relat Res 1996;324:29-38.
10. Cook SD. Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites. Orthopedics 1999;22:669-671.
11. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001;83:151-158.
12. Pecine M, Giltaij LR, Vukicevic S. Orthopaedic applications of osteogenic protein-1 (BMP-7). Int Orthop 2001;25:203-208. (Pubitemid 32802258)
13. Mizumoto Y, Moseley T, Drews M, Cooper VN III, Reddi AH. Acceleration of regenerate ossification during distraction osteogenesis with recombinant human bone morphogenetic protein-7. J Bone Joint Surg Am 2003;85:124-130. (Pubitemid 36951123)
14. Hamdy RC, Amako M, Beckman L, Kawaguchi M, Rauch F, Lauzier D, Steffen T. Effects of osteogenic protein-1 on distraction osteogenesis in rabbits. Bone 2003;33:248-255. (Pubitemid 37117137)
15. Mandu-Hrit M, Haque T, Lauzier D, Kotsiopriftis M, Rauch F, Tabrizian M, Henderson JE, Hamdy RC. Early injection of OP-1 during distraction osteogenesis accelerates new bone formation in rabbits. Growth Factors 2006;24:172-183. (Pubitemid 44669348)
16. Buxton PG, Cobourne MT. Regenerative approaches in the craniofacial region: Manipulating cellular progenitors for orofacial repair. Oral Dis 2007;13:452-460.
17. Mitsukawa N, Satoh K, Suse T, Hosaka Y. Clinical success of mandibular distraction for obstructive sleep apnea resulting from micrognathia in 10 consecutive Japanese young children. J Craniofac Surg 2007;18:948-953. (Pubitemid 47220761)
18. Seeherman H, Wozney J, Li R. Bone morphogenetic protein delivery systems. Spine 2002;27:16-23. (Pubitemid 34912617)
19. Luginbuehl V, Meinel L, Merkle HP, Gander B. Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm 2004;58:197-208. (Pubitemid 39037229)
20. Seeherman H, Wozney JM. Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev 2005;16:329-345. (Pubitemid 40910322)
21. Chen RR, Mooney DJ. Polymeric growth factor delivery strategies for tissue engineering. Pharm Res 2003;20:1103-1112. (Pubitemid 36951832)
22. Winn SR, Uludag H, Hollinger JO. Carrier systems for bone morphogenetic proteins. Clin Orthop Relat Res 1999;367:95-106. (Pubitemid 29501490)
23. Kirker-Head CA. Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev 2000;43:65-92.
24. Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol 2001;19:255-265. (Pubitemid 32537763)
25. Geesink RGT, Hoefnagels NHM, Bulstra SK. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg 1999;81:710-718.
26. Cook SD, Wolfe MW, Salkeld SL, Rueger DC. Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J Bone Joint Surg 1995;77:734-750.
27. Bach FH, Fishman JA, Daniels N, Proimo J, Anderson B, Carpenter CB, Forrow L, Robson SC, Fineberg HV. Uncertainty in xenotransplantation: Individual benefit versus collective risk. Nature Med 1998;4:141-144. (Pubitemid 28137359)
28. Butler D, Wadman M, Lehrman S, Schiermeier Q. Last chance to stop and think on risks of xenotransplants. Nature 1998;391:320-324. (Pubitemid 28093482)
29. DeLustro F, Dasch J, Keefe J, Ellingsworth L. Immune responses to allogeneic and xenogeneic implants of collagen and collagen derivatives. Clin Orthop 1990;260:263-279. (Pubitemid 20381549)
30. Boden SD, Maertin GJ, Morone MA, Ugbo JL, Moskovitz PA. Posterolateral lumbar intertransverse process spine arthodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine 1999;24:1179-1185. (Pubitemid 29279459)
31. Boyan BD, Lohmann CH, Somers A, Niederauer GG, Wozney JM, Dean DD, Carnes DL, Schwartz Z. Potential of porous poly-d,lactide-co-glycolide particles as a carrier for recombinant human bone morphogenetic protein-2 during osteoinducation in vivo. J Biomed Mater Res 1999;46:51-59. (Pubitemid 29233180)
32. Sung HJ, Meredith C, Johnson C, Galis ZS. The effect of scaffold degradation rate on three-dimensional cell growth and angiogenesis. Biomaterials 2004;25:5735-5742. (Pubitemid 38624453)
33. Brekke JH. A rationale for delivery of osteoinductive proteins. Tissue Eng 1996;2:97-114.
34. Kenley R, Marden L, Turek T, Jin L, Ron E, Hollinger JO. Osseous regeneration in the rat calvarium using novel delivery systems for recombinant human bone morphogenetic protein-2 (rhBMP-2). J Biomed Mater Res 1994;28:1139-1147. (Pubitemid 24303139)
35. Higuchi T, Kinoshita A, Takahashi K, Oda S, Ishikawa I. Bone regeneration by recombinant human bone morphogenetic protein-2 in rat mandibular defects. An experimental model of defect filling. J Periodontol 1999;70:1026-1031.
36. Lee SH, Shin H. Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv Drug Deliv Rev 2007;59:339-359. (Pubitemid 46879973)
37. Weber FE, Eyrich G, Grätz KW, Maly FE, Sailer HF. Slow and continuous application of human recombinant bone morphogenetic protein via biodegradable poly(lactide-co-glycolide) foamspheres. Int J Oral Maxillofac Surg 2002;31:60-65.
38. Park GE, Pattison MA, Park K, Webster TJ. Accelerated chondrocyte functions on NaOH-treated PLGA scaffolds. Biomaterials 2005;26:3075-3082. (Pubitemid 39647242)
39. RaviKumar MN. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 2000;3:234-258.
40. Wei G, Jin Q, Giannobile WV, Ma PX. The enhancement of osteogenesis by nano-fibrous scaffolds incorporating rhBMP-7 nanospheres. Biomaterials 2007;28:2087-2096. (Pubitemid 46198923)
41. Hollinger J. Strategies for regenerating bone of the craniofacial complex. Bone 1993;14:575-580. (Pubitemid 23175784)
42. Cai Q, Yang J, Bei JZ, Wang SG. A novel porous cells scaffold made of polylactide-dextran blend by combining phase-separation and particle-leaching techniques. Biomaterials 2002;23:4483-4492. (Pubitemid 36151600)
43. Haidar ZS, Hamdy RC, Tabrizian M. Protein release kinetics for core-shell hybrid nanoparticles based on the layer-bylayer assembly of alginate and chitosan on liposomes. Biomaterials 2008;29:1207-1215.
44. New RRC. Liposomes: A Practical Approach. Oxford: IRC; 1990. pp 256-258.
45. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961;50:874-875.
46. Heerklotz H, Tsamaloukas A, Kita-Tokarczyk K, Strunz P, Gutberlet T. Structural, volumetric, and thermodynamic characterization of a micellar sphere-to-rod transition. J Am Chem Soc 2004;126:16544-16552.
47. Haidar ZS, Azari F, Hamdy RC, Tabrizian M. In vitro characterization and cytotoxic effect of a liposome-based drug delivery system incorporating alternating L-b-L assembly of polyelectrolytes for craniofacial distraction osteogenesis. CBS 2006; Abstract 33.
48. Shiqu YE, Chaoyang W, Xinxing L, Zhen T. Multilayer nanocapsules of polysaccharide chitosan and alginate through layer-by-layer assembly directly on PS nanoparticles for release. J Biomat Sci Polymer Ed 2005;16:909-923.
49. Tabatt K, Sameti M, Olbrich C, Muller RH, Lehr C. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticles-mediated gene transfer. Eur J Pharm Biopharm 2004;57:155-162. (Pubitemid 38283690)
50. Asasutjarit R, Lorenzen SI, Sirivichayakul S, Ruxrungtham K, Ruktanonchai U, Ritthidej GC. Effect of solid lipid nanoparticles formulation compositions on their size. Zeta potential and potential for in vitro phis-hiv-hugag transfection. Pharm Res 2007;24:1098-1107.
51. Chellat F, Tabrizian M, Dumitriu S, Chornet E, Magny P, Rivard CH, Yahia L. Study of biodegradation behaviour of chitosan-xanthan microspheres in simulated physiological media. J Biomed Mater Res 2000;53:592-599. (Pubitemid 30745193)
52. Lindholm TC, Peel SAF, Sàndor GKB, Clokie CML. Intra-oral bone graft used to acquire viable bone cells to be used for tissue engineering. J Can Dent Assoc 2002;68:699.
53. Mizuno M, Kuboki Y. Osteoblast-related gene expression of bone marrow cells during the osteoblastic differentiation induced by type I collagen. J Biochem 2001;129:133-138. (Pubitemid 32150490)
54. Lee DH, Baek HS, Lee MH, Park JH. Production of bone morphogenetic protein-7 using pET expression system. Curr Appl Phys 2005;5:422-425.
55. Wang EA. Bone morphogenetic proteins (BMPs): Therapeutic potential in healing bony defects. Trend Biotechnol 1993;11:379-383. (Pubitemid 23282174)
56. Gohel MC, Panchal MK, Jogani VV. Novel mathematical method for quantitative expression of deviation from the Higuchi model. AAPS Pharm Sci Tech 2000;1:31.